Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Contact sensitizer 2,4-dinitrochlorobenzene is a highly potent human TRPA1 agonist.

Allergy·2014
Same author

Repeated epicutaneous exposures to ovalbumin progressively induce atopic dermatitis-like skin lesions in mice.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2007
Same author

Patch test reactions to cosmetic allergens in 1995-1997 and 2000-2002 in Finland--a multicentre study.

Contact dermatitis·2005
Same author

Phthalic anhydride allergy: development and characterization of optimized hapten-carrier conjugates for improved diagnosis.

Allergy·2002
Same author

Treatment of lichenified atopic eczema with tacrolimus ointment.

Acta dermato-venereologica·2001
Same author

IgE-mediated anaphylaxis to antacid.

Allergy·2001

Related Experiment Video

Updated: Jul 17, 2026

Pharmacologic Induction of Epidermal Melanin and Protection Against Sunburn in a Humanized Mouse Model
12:37

Pharmacologic Induction of Epidermal Melanin and Protection Against Sunburn in a Humanized Mouse Model

Published on: September 7, 2013

Topical FK506--clinical potential or laboratory curiosity?

A I Lauerma1, H I Maibach

  • 1Department of Dermatology, University of California School of Medicine, San Francisco.

Dermatology (Basel, Switzerland)
|January 1, 1994
PubMed
Summary

Topical tacrolimus (FK506) shows promise for inflammatory skin conditions, potentially overcoming limitations of cyclosporine A (CsA) due to better skin penetration and higher potency. Further clinical studies are warranted to confirm its efficacy and safety.

More Related Videos

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

A Protocol for Immunohistochemistry and RNA In-situ Distribution within Early Drosophila Embryo
14:34

A Protocol for Immunohistochemistry and RNA In-situ Distribution within Early Drosophila Embryo

Published on: May 6, 2022

Related Experiment Videos

Last Updated: Jul 17, 2026

Pharmacologic Induction of Epidermal Melanin and Protection Against Sunburn in a Humanized Mouse Model
12:37

Pharmacologic Induction of Epidermal Melanin and Protection Against Sunburn in a Humanized Mouse Model

Published on: September 7, 2013

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

A Protocol for Immunohistochemistry and RNA In-situ Distribution within Early Drosophila Embryo
14:34

A Protocol for Immunohistochemistry and RNA In-situ Distribution within Early Drosophila Embryo

Published on: May 6, 2022

Area of Science:

  • Immunology
  • Dermatology
  • Pharmacology

Background:

  • Cyclosporine A (CsA) is an effective immunosuppressant for inflammatory skin disorders but has systemic side-effects.
  • Topical CsA formulations have shown limited efficacy, likely due to poor skin penetration.
  • Tacrolimus (FK506), a more potent immunosuppressant with a lower molecular weight, presents an alternative.

Purpose of the Study:

  • To evaluate the potential of topical tacrolimus (FK506) as a more effective treatment for inflammatory skin disorders compared to topical CsA.
  • To investigate the skin penetration and anti-inflammatory effects of topical FK506.

Main Methods:

  • Comparison of topical CsA and FK506 penetration in human skin.
  • Assessment of the anti-inflammatory effects of topical FK506 in preclinical models or human subjects.

Main Results:

  • Topical FK506 demonstrates superior skin penetration compared to topical CsA.
  • Topical FK506 appears to effectively suppress skin inflammation in human studies.
  • FK506 is 10-100 times more potent than CsA.

Conclusions:

  • Topical tacrolimus (FK506) exhibits enhanced skin penetration and potent immunosuppressive activity.
  • FK506 represents a promising therapeutic agent for inflammatory skin conditions, potentially offering an improved safety and efficacy profile over CsA.
  • Further clinical trials are recommended to establish the efficacy and safety of topical FK506.